Controlled substances; prohibited equipment related to manufacturing, selling, etc., penalties.
HB2708 amends Virginia’s controlled substances laws to expand and clarify the prohibition on equipment used to manufacture illegal drugs. The bill specifically defines “encapsulating machine” and “tableting machine” and makes it unlawful, except for authorized manufacturers, outsourcing facilities, and pharmacies under the Drug Control Act, to possess, purchase, sell, give, distribute, or possess with intent to transfer such equipment when it is used to manufacture, compound, convert, produce, process, prepare, or otherwise introduce a controlled substance into the human body.
The bill also sets criminal penalties for violations. A general violation is a Class 6 felony, but the offense is elevated to a Class 5 felony if the person knows, intends, or has reasonable cause to believe the conduct will result in the unlawful manufacture of a controlled substance or counterfeit controlled substance involving Schedule I or II drugs, or a controlled substance analog. In practical terms, the measure targets pill-pressing and capsule-filling equipment associated with illicit drug production, while preserving lawful use by regulated pharmaceutical entities.
HB2708 amends § 18.2-248.05 of the Code of Virginia and strengthens the state’s ability to prosecute trafficking in drug-manufacturing equipment, especially pill presses and capsule fillers. It affects individuals and businesses that possess or transfer such equipment, while expressly exempting licensed manufacturers, outsourcing facilities, and pharmacies operating under the Drug Control Act. The bill increases enforcement tools against counterfeit pill production and other illicit controlled substance manufacturing activities.
The bill appears to have received broad bipartisan support and little visible opposition. It advanced unanimously through a House subcommittee, the House Courts of Justice Committee, the full House, and the Senate, with each recorded vote showing no dissenting votes. That voting pattern suggests general agreement that the measure addresses a public safety and drug enforcement concern without creating significant controversy.
No major contention is reflected in the available record, and there are no committee transcripts indicating debate. The main policy line drawn by the bill is between unlawful possession or transfer of pill-making equipment and legitimate pharmaceutical or manufacturing uses. Any potential concern would likely center on ensuring the exemptions for authorized manufacturers, outsourcing facilities, and pharmacies are broad enough to avoid unintended impacts on lawful medical and commercial activity, but no such objection appears in the recorded votes.